UB Paderborn / Katalog / Suche / in CDI

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

British journal of cancer, 2000-02, Vol.82 (4), p.812-817

2000

Link zum Volltext

Verfügbarkeit prüfen

The treatment of advanced renal cell cancer with high-dose oral thalidomide

British journal of cancer, 2001-09, Vol.85 (7), p.953-958

2001

Link zum Volltext

Verfügbarkeit prüfen

59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1

Annals of oncology, 2022-05, Vol.33, p.S149-S149

2022

Link zum Volltext

Verfügbarkeit prüfen

20 Impact of fulvestrant 500 mg/month versus fulvestrant 250 mg/month on bone turnover markers and endometrial thickness: findings from the NEWEST study

European journal of cancer supplements, 2010, Vol.8 (3), p.64-64

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.579-579

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-18-21

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic breast cancer clinical trials

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.552-552

2011

Link zum Volltext

Verfügbarkeit prüfen

OT2-05-01: An Open-Label Positron Emission Tomography Study To Investigate and Quantify Brain and Tumor Penetration of Carbon-11-Labeled Lapatinib in Patients with HER2−Overexpressing Advanced or Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT2-05-01-OT2-05-01

2011

Link zum Volltext

Verfügbarkeit prüfen

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment

Human reproduction (Oxford), 2006-02, Vol.21 (2), p.545-553

2006

Link zum Volltext

Verfügbarkeit prüfen

CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.25-25

2009

Link zum Volltext

Verfügbarkeit prüfen

Occult primary breast carcinoma presenting as axillary lymphadenopathy

Breast (Edinburgh), 2002-10, Vol.11 (5), p.414-418

2002

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy for breast cancer

Annals of medicine (Helsinki), 2000, Vol.32 (1), p.43-50

2000

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy for breast cancer : Advances in Cancer Therapy

Annals of medicine (Helsinki), 2000, Vol.32 (1), p.43-50

2000

Link zum Volltext

Verfügbarkeit prüfen

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT1-02-09-OT1-02-09

2011

Link zum Volltext

Verfügbarkeit prüfen

The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol

Journal of obstetrics and gynaecology, 2010-08, Vol.30 (6), p.596-604

2010

Link zum Volltext

Verfügbarkeit prüfen

Follicular Lymphoma. A Series of 11 Patients with Minimal or no Treatment and Long Survival

Leukemia & lymphoma, 2000, Vol.37 (1-2), p.163-167

2000

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-Neutropenic cancer patients

Medical and pediatric oncology, 1997-03, Vol.28 (3), p.196-200

1997

Link zum Volltext

Verfügbarkeit prüfen

Allogenic bone marrow transplantation in the treatment of malignant hematologic disease

Revista medíca de Chile, 1995-05, Vol.123 (5), p.605

1995

Link zum Volltext

Verfügbarkeit prüfen

Infective complications of the use of permanent central venous catheters in oncology

Revista medíca de Chile, 1992-07, Vol.120 (7), p.783

1992

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

The lancet oncology, 2008-09, Vol.9 (9), p.866-872

2008

Link zum Volltext

Verfügbarkeit prüfen

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1664-1670

2008

Link zum Volltext

Verfügbarkeit prüfen

Combined Surface-Hopping, Dyson Orbital, and B‑Spline Approach for the Computation of Time-Resolved Photoelectron Spectroscopy Signals: The Internal Conversion in Pyrazine

Journal of chemical theory and computation, 2021-08, Vol.17 (8), p.5098-5109

2021

Link zum Volltext

Verfügbarkeit prüfen

Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data

Ecancermedicalscience, 2022-01, Vol.16, p.1338

2022

Link zum Volltext

Verfügbarkeit prüfen

Análisis crítico del tratamiento de la enfermedad hepática grasa no alcohólica

Revista medíca de Chile, 2018-08, Vol.146 (8), p.894-901

2018

Link zum Volltext

Verfügbarkeit prüfen

Assessing the quality and completeness of reporting in health systems guidance for pandemics using the AGREE-HS tool

Journal of global health, 2023-10, Vol.13, p.06050-06050, Article 06050

2023

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

The treatment of advanced renal cell cancer with high-dose oral thalidomide

59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1

20 Impact of fulvestrant 500 mg/month versus fulvestrant 250 mg/month on bone turnover markers and endometrial thickness: findings from the NEWEST study

Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic breast cancer clinical trials

OT2-05-01: An Open-Label Positron Emission Tomography Study To Investigate and Quantify Brain and Tumor Penetration of Carbon-11-Labeled Lapatinib in Patients with HER2−Overexpressing Advanced or Metastatic Breast Cancer

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment

CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer

Occult primary breast carcinoma presenting as axillary lymphadenopathy

Neoadjuvant chemotherapy for breast cancer

Neoadjuvant chemotherapy for breast cancer : Advances in Cancer Therapy

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer

The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol

Follicular Lymphoma. A Series of 11 Patients with Minimal or no Treatment and Long Survival

Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-Neutropenic cancer patients

Allogenic bone marrow transplantation in the treatment of malignant hematologic disease

Infective complications of the use of permanent central venous catheters in oncology

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Combined Surface-Hopping, Dyson Orbital, and B‑Spline Approach for the Computation of Time-Resolved Photoelectron Spectroscopy Signals: The Internal Conversion in Pyrazine

Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data

Análisis crítico del tratamiento de la enfermedad hepática grasa no alcohólica

Assessing the quality and completeness of reporting in health systems guidance for pandemics using the AGREE-HS tool

Suchergebnisse filtern